We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Angelini Pharma Buys Arvelle Therapeutics for $960 Million
Angelini Pharma Buys Arvelle Therapeutics for $960 Million
Italy’s Angelini Pharma announced plans to purchase Swiss drugmaker Arvelle Therapeutics in a deal worth up to $960 million, gaining access to the epileptic seizure drug cenobamate which it plans to market in Europe.